CITIUS ONCOLOGY, INC. (CTOR) — Institutional Holders, Q2 2026
19 institutional investment managers reported a CTOR position on SEC Form 13F-HR for the quarter ended June 30, 2026, with a combined reported value of $9.2M. Every filer is listed below, ranked by position value. Put and call option positions are excluded, and a firm filing several lots or share classes is shown once with its total.
CTOR in Q2 2026: what funds did
Funds that filed a 13F for both Q1 2026 and Q2 2026, by what they did with the common stock. Share counts are adjusted for any split between the two quarters; dollar figures are the change in shares at this quarter’s price.
Biggest buyers
- UBS Group AGAdded · +297,779 sh+$193.6K
- CITADEL ADVISORSNew · +90,586 sh+$58.9K
- Virtu FinancialNew · +21,877 sh+$14.2K
- XTX Topco LtdNew · +20,638 sh+$13.4K
- Tower Research Capital (TRC)New · +13,816 sh+$9.0K
Biggest sellers
- ARMISTICE CAPITALTrimmed · -483,266 sh-$314.2K
- BlackRockSold out · -47,454 sh-$30.9K
- GEODE CAPITAL MANAGEMENTTrimmed · -19,326 sh-$12.6K
- OSAICTrimmed · -9,125 sh-$5.9K
CTOR 13F holders ranked 1–19 of 19
| # | Institution | Shares | Value | % of portfolio | QoQShares vs Q1 2026 |
|---|---|---|---|---|---|
| 1 | ARMISTICE CAPITAL#1 · 8,705,589 sh | 8,705,589 | $5.7M | 0.07% | -5.3% |
| 2 | BANK OF AMERICA#2 · 3,835,160 sh | 3,835,160 | $2.5M | <0.01% | 0.0% |
| 3 | VANGUARD CAPITAL MANAGEMENT#3 · 546,325 sh | 546,325 | $355.1K | 0.00% | +2.2% |
| 4 | UBS Group AG#4 · 334,619 sh | 334,619 | $217.5K | 0.00% | +808.3% |
| 5 | GEODE CAPITAL MANAGEMENT#5 · 245,407 sh | 245,407 | $159.5K | 0.00% | -7.3% |
| 6 | VANGUARD FIDUCIARY#6 · 121,910 sh | 121,910 | $79.2K | 0.00% | 0.0% |
| 7 | IFP Advisors#7 · 107,424 sh | 107,424 | $69.8K | — | 0.0% |
| 8 | CITADEL ADVISORS#8 · 90,586 sh | 90,586 | $58.9K | 0.00% | New |
| 9 | NORTHERN#9 · 45,746 sh | 45,746 | $29.7K | 0.00% | 0.0% |
| 10 | STATE STREET#10 · 42,900 sh | 42,900 | $27.9K | 0.00% | 0.0% |
| 11 | Virtu Financial#11 · 21,877 sh | 21,877 | $14.0K | <0.01% | New |
| 12 | XTX Topco Ltd#12 · 20,638 sh | 20,638 | $13.4K | <0.01% | New |
| 13 | Tower Research Capital (TRC)#13 · 13,816 sh | 13,816 | $9.0K | <0.01% | New |
| 14 | Arkadios Wealth Advisors#14 · 11,666 sh | 11,666 | $7.6K | <0.01% | 0.0% |
| 15 | OSAIC#15 · 1,000 sh | 1,000 | $650.00 | 0.00% | -90.1% |
| 16 | WELLS FARGO & COMPANY#16 · 500 sh | 500 | $325.00 | 0.00% | New |
| 17 | BARCLAYS PLC#17 · 90 sh | 90 | $59.00 | 0.00% | New |
| 18 | MORGAN STANLEY#18 · 23 sh | 23 | $15.00 | 0.00% | New |
| 19 | Caitong International Asset Management , Ltd#19 · 1 sh | 1 | $1.00 | 0.00% | 0.0% |
Funds that sold out of CTOR in Q2 2026 (2)
Held CTOR at the end of Q1 2026 and filed a Q2 2026 13F without it. Not in the list above, because they no longer hold it. Largest prior position first.
| Institution | Shares sold | Value in Q1 2026 |
|---|---|---|
| BlackRock47,454 sh | 47,454 | $29.4K |
| ROYAL BANK OF CANADA186 sh | 186 | $0.00 |
Source: Form 13F-HR filings on SEC EDGAR, Q2 2026. Values are as reported by each manager at quarter end. “% of portfolio” is the position’s share of the manager’s total reported 13F value for the same quarter. “New” means the manager filed a 13F for Q1 2026 without this position; a dash means no comparison is available. Where a manager’s own filing is internally inconsistent its value is withheld and it is listed last. 13F data shows reported holdings, not recommendations.